Tesaro Pumped As PARP Inhibitor Zejula Gets CHMP Nod
Executive Summary
While AstraZeneca's rival drug Lynparza is catching up across the Atlantic, this likely approval for Tesaro's ovarian cancer drug will boost the US firm as it aims to make a strong start in the European market.
You may also be interested in...
EU CHMP To Decide On New Drugs For Asthma, Diabetes, Hemophilia A, Ovarian Cancer – And Roche’s Ocrevus
Products for a wide range of diseases are expecting a CHMP opinion this week, including orphan drugs for ovarian cancer, eosinophilic esophagitis, and CMV infection, and therapies for asthma, diabetes, and hemophilia A. Roche will be hoping its multiple sclerosis drug Ocrevus can finally clear the CHMP hurdle.
Not Just Herceptin Biosimilar: Additional 12 Drugs Set For EU Marketing Approval After CHMP Nod
New treatments for plaque psoriasis and ovarian and prostate cancer join the first Herceptin biosimilar and several other products in garnering recommendations for EU marketing approval at September's meeting of EMA's key scientific committee, the CHMP. No decision was taken on Roche’s new MS drug, Ocrevus, and earlier negative opinions of three other products were upheld.
Clovis CEO Sees Rosy Future With Rubraca
Success in the ARIEL3 trial for its ovarian cancer agent and a collaboration with Bristol-Myers Squibb has put Clovis in a healthy position, CEO Patrick Mahaffy tells Scrip.